Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tramadol; celecoxib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| tramadol HCl ER; celecoxib | DRUG | - |
Inclusion Criteria: * Patients with American College of Rheumatology (ACR) Functional Class I-III OA of the knee or hip; * Patients with involvement of knee or hip joint that warrants treatment with COX-2 selective inhibitors, NSAIDs, acetaminophen, or opioid analgesics for at least 75 of the 90 da...
Top 4 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Retatrutide, LY3016859, LY3556050, LY3526318, LY3857210 |
| Fortress Biotech, Inc. | FBIO | 1 | PHASE3 | Tramadol |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | MK-6916 |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
Tramadol; celecoxib refers to a development program combining extended release tramadol HCl with celecoxib for the treatment of chronic pain. Bausch Health Companies Inc. (ticker BHC) is developing this combination, which is in Phase 3 clinical development. Both components are small molecule agents.
Tramadol; celecoxib is being developed for chronic pain. The Phase 3 trial for this program evaluated extended release tramadol HCl at 100 mg, 200 mg and 300 mg doses for moderate to severe pain due to osteoarthritis. The program has not been approved and remains investigational.
Bausch Health Companies Inc., which trades under the ticker BHC, is the developer of the tramadol; celecoxib program. The company is advancing this combination for chronic pain through Phase 3 clinical development.
Tramadol; celecoxib is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The program is investigational and has not received FDA approval for any indication.
The tramadol; celecoxib program includes the completed Phase 3 trial NCT00348452, titled A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis. It enrolled 1,000 participants aged 18 years and older.
Tramadol; celecoxib is also known as tramadol HCl ER and celecoxib. The extended release tramadol HCl component was studied at 100 mg, 200 mg and 300 mg doses in the Phase 3 osteoarthritis pain trial NCT00348452.